Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 10.44%30.74B | 5.42%19.98B | 0.94%9.76B | 1.73%37.05B | 2.20%27.84B | 4.01%18.95B | 4.93%9.66B | 13.67%36.42B | 14.59%27.24B | 17.28%18.22B |
| Special items of operating revenue | 30.55%22.36M | ---- | -24.49%3.94M | ---- | -13.66%17.13M | ---- | -3.92%5.22M | ---- | 28.11%19.84M | ---- |
| Operating income | 10.45%30.77B | 5.42%19.98B | 0.93%9.76B | 1.73%37.05B | 2.19%27.86B | 4.01%18.95B | 4.92%9.67B | 13.67%36.42B | 14.59%27.26B | 17.28%18.22B |
| Cost of sales | ---- | -6.22%-15.33B | ---- | 2.16%-28.2B | ---- | -1.46%-14.43B | ---- | -12.39%-28.82B | ---- | -16.38%-14.22B |
| Operating expenses | -11.69%-23.62B | -6.22%-15.33B | -1.50%-7.47B | 2.16%-28.2B | 1.20%-21.15B | -1.46%-14.43B | -1.05%-7.36B | -12.39%-28.82B | -13.93%-21.41B | -16.38%-14.22B |
| Gross profit | 6.53%7.14B | 2.87%4.65B | -0.87%2.29B | 16.46%8.85B | 14.55%6.71B | 13.05%4.52B | 19.48%2.31B | 18.81%7.6B | 17.11%5.85B | 20.57%4B |
| Selling expenses | 3.59%-667.26M | 10.98%-420.36M | 5.64%-235.23M | -17.47%-1.07B | 7.74%-692.09M | 22.46%-472.19M | 0.88%-249.3M | -9.47%-910.38M | -16.67%-750.13M | -43.33%-608.96M |
| Administrative expenses | -16.35%-1.02B | -10.15%-622.65M | -6.70%-303.95M | -24.52%-1.49B | -3.99%-880.86M | -8.01%-565.26M | -7.71%-284.86M | -11.80%-1.2B | -10.92%-847.09M | -7.47%-523.33M |
| Research and development expenses | -1.55%-1.23B | 2.45%-813.48M | 19.51%-375.77M | 3.30%-1.52B | 6.86%-1.21B | -0.71%-833.93M | -10.62%-466.83M | -13.15%-1.57B | -9.52%-1.3B | -5.26%-828.03M |
| Profit from asset sales | -4.68%6.64M | ---- | -93.22%167.12K | ---- | 106.81%6.97M | ---- | 170.28%2.47M | ---- | -65.72%3.37M | ---- |
| Revaluation surplus | 418.66%356.29M | ---- | -41.75%19.56M | ---- | -15.54%68.69M | ---- | -18.14%33.58M | ---- | 327.58%81.33M | ---- |
| -Changes in the fair value of other assets | 418.66%356.29M | ---- | -41.75%19.56M | ---- | -15.54%68.69M | ---- | -18.14%33.58M | ---- | 327.58%81.33M | ---- |
| Impairment and provision | 4.52%-260.72M | -33.26%-196.17M | -89.29%-82.39M | -407.89%-157.72M | -467.10%-273.06M | -620.42%-147.21M | -69.64%-43.53M | 137.31%51.23M | 126.62%74.38M | 79.36%-20.43M |
| -Other impairment is provision | 4.52%-260.72M | -33.26%-196.17M | -89.29%-82.39M | -407.89%-157.72M | -467.10%-273.06M | -620.42%-147.21M | -69.64%-43.53M | 137.31%51.23M | 126.62%74.38M | 79.36%-20.43M |
| Operating interest expense | 42.49%-4.64M | ---- | -4.77%-2.38M | ---- | 26.41%-8.07M | ---- | 32.84%-2.28M | ---- | -473.77%-10.96M | ---- |
| Special items of operating profit | -38.39%331M | 25.92%544.39M | -19.54%141.08M | 75.16%838.86M | 95.17%537.22M | 29.26%432.33M | 72.90%175.34M | 34.38%478.91M | -41.48%275.26M | -12.41%334.47M |
| Operating profit | 8.92%4.52B | 7.08%3.15B | -2.18%1.41B | 22.47%5.45B | 27.55%4.15B | 24.72%2.94B | 34.92%1.45B | 33.86%4.45B | 31.89%3.26B | 23.75%2.36B |
| Financing cost | -4.16%-167.34M | 7.25%-126.91M | -4.37%-55.97M | 23.33%-297.95M | -75.00%-160.65M | 18.82%-136.82M | -35.55%-53.62M | -46.42%-388.6M | -9.61%-91.8M | -22.15%-168.54M |
| Share of profits of associates | ---- | -42.31%17.89M | ---- | 2.88%48.32M | ---- | 32.95%31M | ---- | 102.90%46.97M | ---- | 37.62%23.32M |
| Share of profit from joint venture company | ---- | -71.47%1.3M | ---- | 7.55%6.34M | ---- | 911.28%4.57M | ---- | 16.65%5.89M | ---- | 74.52%452K |
| Adjustment items of earning before tax | -77.45%2.7M | ---- | -164.91%-729.42K | ---- | 201.36%11.95M | ---- | -48.34%1.12M | ---- | -185.00%-11.79M | ---- |
| Earning before tax | 8.86%4.36B | 7.10%3.04B | -2.56%1.36B | 26.55%5.21B | 27.02%4B | 28.31%2.84B | 34.73%1.39B | 33.27%4.12B | 31.41%3.15B | 24.01%2.21B |
| Tax | 4.99%-654.54M | 5.96%-456.8M | -8.96%-240.5M | -59.01%-980.57M | -34.42%-688.95M | -29.66%-485.76M | -31.01%-220.73M | -33.46%-616.67M | -37.21%-512.53M | -42.11%-374.65M |
| After-tax profit from continuing operations | 11.74%3.7B | 9.80%2.58B | -4.73%1.12B | 20.83%4.23B | 25.58%3.32B | 28.03%2.35B | 35.45%1.17B | 33.24%3.5B | 30.34%2.64B | 20.87%1.84B |
| Earning after tax | 11.74%3.7B | 9.80%2.58B | -4.73%1.12B | 20.83%4.23B | 25.58%3.32B | 28.03%2.35B | 35.45%1.17B | 33.24%3.5B | 30.34%2.64B | 20.87%1.84B |
| Minority profit | -76.80%59.58M | -69.45%53.79M | -77.95%28.87M | 43.52%287.41M | 48.64%256.76M | 35.49%176.05M | 57.79%130.93M | 123.08%200.26M | 171.79%172.74M | 138.27%129.94M |
| Profit attributable to shareholders | 19.17%3.64B | 16.22%2.53B | 4.47%1.09B | 19.45%3.94B | 23.97%3.06B | 27.46%2.17B | 33.08%1.04B | 30.06%3.3B | 25.76%2.47B | 16.50%1.71B |
| Basic earnings per share | 20.57%2.075 | 16.26%1.43 | 4.08%0.612 | 18.37%2.2162 | 22.93%1.721 | 26.80%1.23 | 31.84%0.588 | 28.78%1.8722 | 24.44%1.4 | 15.48%0.97 |
| Diluted earnings per share | 20.93%2.074 | 17.21%1.43 | 4.62%0.612 | 18.79%2.2106 | 22.76%1.715 | 25.77%1.22 | 32.05%0.585 | 28.74%1.8609 | 24.51%1.397 | 15.48%0.97 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.